Lynx1 Capital Management LP
Lynx1 Capital Management LP reported 31 holdings worth US$646M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Lynx1 Capital Management LP reported 31 holdings worth US$646M as of Sep 30, 2026. Largest: Cullinan Therapeutics, Inc., Stoke Therapeutics, Inc. and C4 Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 31
- Value as reported
- US$646M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Cullinan Therapeutics, Inc. | 8.96M | US$138M | 21.3% |
| Stoke Therapeutics, Inc. | 3.9M | US$101M | 15.7% |
| C4 Therapeutics, Inc. | 7.53M | US$25.1M | 3.9% |
| Precision BioSciences, Inc. | 2.76M | US$17.3M | 2.7% |
| Agios Pharmaceuticals, Inc. | 473K | US$15.7M | 2.4% |
| Korro Bio, Inc. | 1.54M | US$15.3M | 2.4% |
| Neuphoria Therapeutics Inc. | 875K | US$3.12M | 0.48% |
| Passage Bio, Inc. | 674K | US$3.03M | 0.47% |
| TScan Therapeutics, Inc. | 8.02M | US$2.52M | 0.39% |
| Kazia Therapeutics Ltd | 226K | US$2.17M | 0.34% |
| Pliant Therapeutics, Inc. | 1.8M | US$1.94M | 0.30% |
| Entrada Therapeutics, Inc. | 279K | US$1.77M | 0.27% |
| Surrozen, Inc. | 20,000 | US$644K | 0.10% |
| Werewolf Therapeutics, Inc. | 658K | US$607K | 0.09% |
| Xencor, Inc. | 18,194 | US$454K | 0.07% |
| Immunocore Holdings plc | 14,300 | US$433K | 0.07% |
| Dyne Therapeutics, Inc. | 25,000 | US$403K | 0.06% |
| Traws Pharma, Inc. | 559K | US$332K | 0.05% |
| Denali Therapeutics Inc. | 11,658 | US$241K | 0.04% |
| Absci Corporation | 21,245 | US$229K | 0.04% |
| Foghorn Therapeutics Inc. | 61,588 | US$220K | 0.03% |
| Avalo Therapeutics, Inc. | 10,100 | US$155K | 0.02% |
| Prime Medicine, Inc. | 45,000 | US$137K | 0.02% |
| Bolt Biotherapeutics, Inc. | 30,800 | US$113K | 0.02% |
| Eupraxia Pharmaceuticals, Inc. | 10,000 | US$91,000 | 0.01% |
| Nuvation Bio Inc. | 16,029 | US$89,762 | 0.01% |
| Inhibikase Therapeutics, Inc. | 20,000 | US$1,201 | <0.01% |
| CG Oncology, Inc. | 0 | US$0 | 0.00% |
| VYNE Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related